Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

In a meta-analysis of over 61 million participants, it was found that AD patients have a 37% risk of developing IBD and similar conditions.

Patients with Atopic Dermatitis Are More Susceptible to Developing Inflammatory Bowel Disease

The latest publication from OJM Group provides 7 core strategies for dermatologists looking to meet their financial goals.

Wealth Strategies for Today’s Physician: David Mandell, JD, MBA, Shares Insights from New Playbook

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Jackson discusses EVO756, a promising MRGPRX2 antagonist targeting mast cells to treat chronic inflammatory diseases like spontaneous urticaria.

Exploring EVO756 in Chronic Inflammatory Disease Treatment: Q&A with Evommune's Mark Jackson, MD

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Catch up on exclusive interviews with Christopher Bunick, MD, PhD; Raj Chovatiya, MD, PhD; and Alexander Egeberg, MD, PhD, from quarter 4 dermatologic conferences.

2024 Insights: Unmet Needs, Therapeutic Innovations, and Pivotal Findings in Chronic Hand Eczema